Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesi...(jective perceptions of hunger and ...),Health

fullness" will be presented by Nico Pannacciulli, MD, PhD, Sunday,

October 5 at 5:30 p.m. PT (8:30 p.m. ET).

7. Poster 489-P: "Central activation and weight-lowering actions of

AC164209, a peptide hybrid linking a glucagon-like peptide-1 (GLP-1)

receptor agonist and an amylin mimetic" will be presented by Christine

Mack, PhD, Sunday, October 5 at 5:30 p.m. PT (8:30 p.m. ET).

8. Corporate-sponsored symposium: "Emerging Peptide Hormone Therapies for

the Treatment of Obesity: Mechanisms of Action, Clinical Safety and

Efficacy." This medical educational symposium will help healthcare

providers understand the peptide hormone approach to the treatment of

obesity. The event will be chaired by George A. Bray, MD, MACP,

Saturday, October 4 at 7:15 p.m. PT (10:15 p.m. ET). This symposium

is supported by an unrestricted educational grant from Amylin

Pharmaceuticals.

9. Corporate-sponsored symposium: "Reducing CVD Risk: Emerging Science

and Therapeutic Options in the Management of Obesity and Type 2

Diabetes." This medical education symposium will help healthcare

providers understand new science and therapeutic options to reducing

cardiovascular disease risk in the treatment of obesity and type 2

diabetes. The event will be chaired by Robert H. Eckel, MD, Monday,

October 6 at 5:45 p.m. PT (8:45 p.m. ET). This symposium is supported

by an unrestricted educational grant from Amylin Pharmaceuticals and

Eli Lilly and Company.

A full list of all Amylin abstracts being presented at the 2008 Obesity Society meeting is available at: http://www.obesity.org/annualmeeting08/OS_Phoenix08_Final_Program.pdf .

About Obesity